Del-Pesti Centrumkorhaz Orszagos Hematologiai Es Infektologiai Intezet
- Address
- lock Available on a paid plan
Cardiovascular Diseases
Clinical research at Del-Pesti Centrumkorhaz Orszagos Hematologiai Es Infektologiai Intezet focuses on cardiovascular diseases, especially atherosclerotic cardiovascular disease and related risk conditions. The studies are designed to test whether new treatments can better prevent serious heart and blood vessel events in people at elevated risk.
- Prevention of major adverse cardiovascular events in high-risk patients
- Evaluation of therapies for atherosclerotic heart and blood vessel disease
- Research on reducing cardiovascular risk linked to lipoprotein disorders
These trials aim to improve treatment effectiveness and support earlier prevention strategies for patients with significant cardiovascular risk.
Nutritional and Metabolic Diseases
The site also conducts studies in nutritional and metabolic diseases, with a strong emphasis on obesity and overweight. This research explores whether newer therapies can help lower weight-related health risks and improve long-term outcomes for adults living with metabolic conditions.
- Testing treatment approaches for obesity
- Clinical research in overweight and related metabolic risk
- Assessing therapies that may reduce morbidity and mortality in obesity
Overall, the trials are aimed at improving disease control, lowering complications, and supporting better prevention of cardiovascular and metabolic problems.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 4 of 9 therapeutic areas and 15 of 183 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 181 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 17 by active trials.
- 1Novartis Pharma AG2active
lock +16 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Novartis Pharma AG10trials
lock +13 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 332 other sites in Hungary
Therapeutic Area Benchmark — Hungary
Select a therapeutic area to compare against other sites in Hungary.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Hungary
Market Share
Country: Hungary
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Del-Pesti Centrumkorhaz Orszagos Hematologiai Es Infektologiai Intezet
lock Showing 1 of 82 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Multicenter, Randomized, Double-Blind, Placebo-Controlled, 2-Stage Trial to Evaluate Efficacy and Safety of Telitacicept Compared to Placebo in Patients with Moderately to Severely Active Systemic Lupus Erythematosus (REMESLE-1) | Remegen Co. Ltd. | Phase III | Not Yet Recruiting | Nov 2022 | Jan 2025 |
IMP list
lock Showing 1 of 183 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Dexamethasone | 11 | Unknown | 2016-11-21 | 2025-04-17 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.